Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00572247
Other study ID # 1R34MH077282-01A1
Secondary ID 10575
Status Completed
Phase N/A
First received December 11, 2007
Last updated March 5, 2012
Start date January 2007
Est. completion date December 2010

Study information

Verified date March 2012
Source University of Kansas Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The primary aim of the project is to examine the efficacy of the Psychiatric Rehabilitation Weight Loss program in reduction of weight and body mass index (BMI.


Description:

The study involves 144 individuals who will be randomly assigned to the intervention group or treatment as usual group(control group). All Participants will undergo baseline assessment, assessment at week 12, week 24 and in year from baseline.


Recruitment information / eligibility

Status Completed
Enrollment 133
Est. completion date December 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- A diagnosis of serious mental illness,

- Age 18 - 65

- BMI > 25

- Medication stable (there have been no changes in antipsychotic medications or mood stabilizers for the last 3 months).

Exclusion Criteria:

- Current or history of eating disorder

- Pregnant or breast feeding

- Uncontrolled HTN

- Severe coronary artery disease

- Severe valvular disease

- Uncontrolled diabetes

- Sustained arrhythmia

- Insulin using severe physical limitations

- Severe Lung Disorders

- Diagnosis of MR or dementia

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Behavioral:
Psychiatric Rehabilitation Approach to Weight Loss
The use of psychiatric rehabilitation as a way to lose weight

Locations

Country Name City State
United States University of Kansas Medical Center Kansas City Kansas

Sponsors (2)

Lead Sponsor Collaborator
University of Kansas Medical Center National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The reduction of weight and Body Mass Index (BMI) Week 12, Week 24, 1 Year from Baseline Visit No
Secondary Measure of waist circumference, health promotion practices, dietary intake assessment of physical activity Baseline, 12 Weeks, 24 weeks, 1 year No
See also
  Status Clinical Trial Phase
Recruiting NCT04608032 - Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia N/A
Terminated NCT00660595 - Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose Phase 3
Completed NCT02655172 - Have a Good Grasp of the Worldthe World N/A
Completed NCT01606436 - A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia Phase 1
Completed NCT01729650 - Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) N/A
Completed NCT02525315 - Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations Phase 2
Completed NCT00488319 - Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. Phase 3
Completed NCT00088491 - Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia Phase 3
Completed NCT01279213 - Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia Phase 4
Completed NCT00600756 - Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Phase 3
Completed NCT00491569 - Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia Phase 2
Completed NCT00328276 - Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia Phase 2
Completed NCT00485823 - Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Phase 4
Active, not recruiting NCT00161408 - Psychological Intervention for Relapse Prevention in First Episode Schizophrenia N/A
Terminated NCT05164289 - Interest of EMDR Schizophrenic Disorders
Withdrawn NCT00276263 - Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia Phase 2
Completed NCT00088465 - Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder Phase 3
Withdrawn NCT02654405 - Sodium Butyrate For Improving Cognitive Function In Schizophrenia Phase 2/Phase 3
Completed NCT02544516 - Upside Down, Give me the Handle N/A
Completed NCT00960219 - D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia Phase 2